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Background. Management of unresectable pediatric low-grade glioma and glioneuronal 
tumor (LGG/LGGNT) is controversial. There are no validated prognostic features to guide 
use of radiation therapy (RT). Our study aimed to identify negative prognostic features in 
patients treated with RT using clinicopathologic and molecular data and validate these 
findings in an external dataset.  
Methods. Children with non-metastatic, biopsy-proven unresectable LGG/LGGNT treated 
with RT at a single institution between 1997 and 2017 were identified. Recursive partitioning 
analysis (RPA) was used to stratify patients into low- and high-risk prognostic groups based 
on overall survival (OS). CNS9702 data were used for validation.  
Results. One hundred and fifty patients met inclusion criteria. Median follow-up was 11.4 
years. RPA yielded low- and high-risk groups with 10-year OS of 95.6% vs. 76.4% (95% CI: 
88.7% - 98.4% vs. 59.3% – 87.1%, p=0.003), respectively. These risk groups were validated 
using CNS9702 dataset (n=48) (4-year OS: low-risk vs. high-risk: 100% vs. 64%, p<0.001).  
High-risk tumors included diffuse astrocytoma or location within thalamus/midbrain. Low-
risk tumors included pilocytic astrocytoma/ganglioglioma located outside of the 
thalamus/midbrain. In the subgroup with known BRAF status (n=49), risk stratification 
remained prognostic independent of BRAF alteration (V600E or fusion).  Within the high-risk 
group, delayed RT, defined as RT after at least one line of chemotherapy, was associated with 
a further decrement in overall survival (p=0.021).   
Conclusion. A high-risk subgroup of patients, defined by diffuse astrocytoma histology or 
midbrain/thalamus tumor location, have suboptimal long-term survival and might benefit 
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Key points:  
 Management of unresectable pediatric low-grade glioma is controversial.  
 We identify and validate a high-risk cohort with suboptimal long-term survival. 
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Importance of Study: 
There are no validated prognostic features to guide use of radiation therapy in unresectable 
pediatric low-grade gliomas and glioneuronal tumors. Optimal management of these tumors 
is controversial. Using clinicopathologic and molecular data from patients treated 
homogenously with radiation therapy, we identified and validated low- and high-risk groups 
with significantly disparate 10-year overall survival. Risk stratification remained significant 
independent of BRAF alteration (V600E or fusion). Within the high-risk group, delayed 
radiation therapy, defined as radiation therapy administered after at least one line of 
chemotherapy, was associated with a further decrement in overall survival. High-risk tumors, 
defined by diffuse astrocytoma histology or thalamic/midbrain location, might benefit from 
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Pediatric low-grade gliomas (LGGs) and glioneuronal tumors (LGGNTs) represent 
heterogeneous diseases with multiple treatment options and varied outcomes depending on 
clinicopathologic variables and treatment modality.
1
 Several selection biases drive the choice 
of therapy. For tumors that can be totally resected, no adjuvant therapy is required and 
outcomes are usually excellent.
2,3
 For unresectable tumors, optimal management is 
controversial. Despite the efficacy of radiation therapy (RT) in locally controlling 
unresectable disease, concerns regarding RT-related adverse effects
4
 in young children have 
resulted in a preference for initially administering chemotherapy or targeted therapy, both of 
which are associated with inferior progression-free survival (PFS) when compared to RT.
5–9
 
RT is recommended for older children or for those whose tumors have progressed on 
systemic therapy. For patients who are candidates for RT, there are no validated criteria for 
risk stratification based on overall survival (OS) and the timing of RT remains controversial 
as it is assumed that all patients can be successfully salvaged with RT. As a result, patients 
might experience significant morbidity and mortality due to repeated tumor progressions 
prior to RT in an otherwise curable disease.
10
 This highlights the need for a data-driven 
approach, incorporating both clinicopathologic and molecular data, to risk-stratify this patient 
population, with the goal of facilitating treatment decisions and thereby optimizing outcomes 
for these patients.  
 
We used a cohort of patients who were uniformly treated with RT at St. Jude Children’s 
Research Hospital (St. Jude) with a median follow-up of greater than 10 years to identify 
critical clinicopathologic and molecular variables associated with OS. Patents were treated 
either on an institutional phase II study, RT1, (ClinicalTrials.gov identifier: NCT00187226), 






/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noaa031/5734990 by St. Jude C
hildren's R
esearch H










NCT00238264). BRAF status was available for some patients. Our focus was on OS, in order 
to identify high-risk patients who could not be successfully salvaged. We hypothesized that 
clinicopathologic features along with molecular data could be used to risk-stratify patients 
based on OS.  We employed recursive partitioning analysis (RPA) to divide patients with 
LGG/LGGNT into two prognostic groups with clinical utility and subsequently validated the 
model using an external prospective dataset from the Children’s Cancer and Leukemia 
Group’s (CCLG) CNS9702 trial, which included patients who were treated in a similar 
manner to those at St. Jude.  
 
Materials and Methods 
Study Population – St. Jude Cohort 
Patients with LGG/LGGNT treated with focal RT between 1997 and 2017 at St. Jude were 
identified. Indications for RT included radiographic progression of disease, symptomatic 
disease or deterioration in visual field/acuity. Patients could have been treated with 
chemotherapy prior to RT. Those who underwent RT between 1997 and 2010 were treated on 
a phase II institutional protocol, RT1, (ClinicalTrials.gov identifier: NCT00187226) and 
those who underwent RT after 2010 were treated according to Children’s Oncology Group 
Study, ACNS0221 (ClinicalTrials.gov identifier: NCT00238264). Exclusion criteria are 
shown in the CONSORT diagram (Figure 1). A total of 150 patients were included for 
analysis. Tumors in relatively uncommon anatomic sites such as the spinal cord (n=3, 2 had 
metastatic disease) and cerebral cortex (n=8, 4 were diagnosed as LGG, not otherwise 
specified) were excluded. Patients who did not undergo a biopsy (n=19) or patients whose 
tumors were diagnosed as LGG, not otherwise specified (n=12) due to insufficient biopsy 
material were excluded. Additionally, patients with metastatic disease (n=9), and prior 
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histological entities represented by only a single patient, such as angiocentric glioma (n=1), 
neurocytoma (n=1) and gangliocytoma (n=1), were also excluded. The study was approved 
by the St. Jude Institutional Review Board (#Pro00009006).  
Study Population – CNS9702 Cohort 
The external validation dataset, CNS9702, was a population-based study that enrolled 
patients younger than 16 years of age with LGG/LGGNT across 22 treatment centers in the 
United Kingdom. Treatment strategy, methodology and results for the entire study population 
have been previously reported.
11
  The dataset we used for validation consisted of patients on 
CNS9702 who underwent RT as first line of therapy.  The exclusion and inclusion criteria for 
the external validation dataset were identical to that of the St. Jude dataset (Figure 1). A total 
of 48 patients were included for analysis. As with the St. Jude dataset, the most common 
reason for exclusion was lack of a biopsy (n=12). Other reasons for exclusion included 
location (spinal cord: n=9, cerebral cortex: n=9), metastatic disease (n=4), the designation of 
LGG, not otherwise specified (n=2) and rare histologic entities represented by a single 
patient, such as dysembryoplastic neuroepithelial tumor (n=1).  
Histopathologic Review 
For both study cohorts, histopathology was centrally reviewed by a single neuropathologist 
(DWE). For each case, standard hematoxylin and eosin–stained histopathologic preparations 
were supplemented by immunohistochemistry on 5μm formalin-fixed paraffin-embedded 
(FFPE) tissue sections. For the St. Jude cohort, BRAF alterations were identified when tissue 
was available. A mouse monoclonal antibody (Ventana, cat. no. 7990-4855; prediluted) was 
used to detect BRAF V600E-mutant protein.
12
 Interphase fluorescence in situ hybridization 
was used to detect chromosome 7q34 duplication, a surrogate marker for KIAA1549-BRAF 
fusion, using a probe developed in-house.
13
 The presence of the histone H3K27M mutation 
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For the St. Jude cohort, the extent of surgical resection was defined using postoperative MRI, 
along with clinical and operative data. Gross total resection (GTR) was defined as the 
removal of all tumor-related T1 enhancement and T2 FLAIR abnormality, excluding signal 
change thought to be post-surgical. Subtotal resection (STR) was defined as presence of 
residual tumor–related T1 enhancement and/or T2 FLAIR abnormalities visible on 
postoperative MRI. Biopsy was defined as sampling rather than resection of tumor. For the 
CNS9702 Cohort, primary surgical resection or biopsy was recommended for all patients 
except those with neurofibromatosis type 1 (NF1) and those with chiasmatic/hypothalamic 
tumors consistent with optic pathway glioma, as described previously.
11
 Extent of resection 
was based on the local operative report and on the postoperative MRI following the 
recommendation of the Brain Tumor Subcommittee.
14
 GTR was defined as without 
measurable disease. STR was defined as residual tumor of a measurable size.  
Radiation Therapy  
For the St. Jude cohort, RT was delivered with a 3D conformal or intensity-modulated 
radiation technique to a total dose of 54 GyRBE in 1.8 GyRBE fractions over 6 weeks. The 
gross tumor volume (GTV) included both the cystic and solid components of the tumor and 
was defined by T2/FLAIR hyperintensity and T1 enhancement (if present). In patients who 
underwent surgery before RT, the GTV was defined as the surgical bed and any residual 
T2/FLAIR hyperintensity or T1 enhancement. The clinical target volume (CTV) margin was 
1 cm for patients treated from 1997 to 2006. The CTV margin was 0.5 cm for patients treated 
after 2006. For patients treated with photon therapy, a planning target volume (PTV) margin 
of 0.5 or 0.3 cm was used. For patients treated with pencil-beam scanning proton therapy, 
scenario-based optimization was used with a 3-mm positional uncertainty and a 3% range 






/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noaa031/5734990 by St. Jude C
hildren's R
esearch H










proton therapy, the total dose was reduced to 52.2 GyRBE to minimize risk of optic 
chiasm/nerve toxicity.  For the CNS9702 Cohort, similar focal RT was delivered to 54 
GyRBE for children >5 years and 50 GyRBE for children <5 years, as described previously.
11
 
All tumors were treated with a CTV margin of 1-2 cm.  
Radiographic Evaluation 
For the St. Jude Cohort, all patients underwent brain MRI at baseline, every 3 months for the 
first 2 years, every 6 months through 5 years, and yearly thereafter. Radiographic response 
was categorized according to RECIST criteria, with radiographic progression being defined 
as >25% tumor growth or the appearance of new lesions.
15
 For the CNS9702 cohort, tumor 




Outcome Measures and Variable Definitions  
The primary outcome measure was OS. Secondary outcomes were progression-free survival 
(PFS) and cumulative incidence of secondary malignancies. Survival time was calculated 
from start of RT to death or last follow-up, whichever occurred first. Time to progression was 
calculated from start of RT to progression, death or last follow-up, whichever occurred first. 
All outcome measures were calculated in an identical fashion for both cohorts. Tumor size, 
measured prior to RT, was defined as the largest tumor diameter, and was dichotomized as 
6cm and <6cm, consistent with adult LGG studies.
16
 Tumors involving the optic pathways 
and/or hypothalamus were grouped together, consistent with published data.
17
 Tumors 
involving the thalamus and/or midbrain were grouped together, as were those involving the 
pons and/or medulla, as both structures were often involved. Delayed RT was defined as RT 
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Frequency distributions between groups were assessed with the Fisher exact test for 
categorical variables and Wilcoxon rank sum test for continuous variables. Survival analysis 
was computed using the Kaplan-Meier method and log-rank test was used to compare curves. 
Prognostic variables were identified via Cox proportional hazards. Variables significant on 
Cox univariate analysis (p<0.05) were considered for multivariate analysis. Cumulative 
incidence of secondary malignancies was estimated using death as a competing risk. All 
statistical tests were 2-sided. Statistical analyses were performed with Stata software (2014 
release, StataCorp, College Station, TX).  
Recursive partitioning analysis (RPA) was used to devise high-risk and low-risk prognostic 
groups based on OS. RPA divides patients into homogeneous groups based on chosen 
covariates with respect to a predetermined outcome parameter, such as OS.
18
 We employed 
classification and regression tree analysis (CART) 
19
  in Stata to generate statistically 
significant divisions (p0.05), with respect to OS, based on variables that were significant on 
Cox multivariate analysis with the exception of tumor size. CART in Stata is specifically for 
failure time data and uses the martingale residuals of a Cox model to approximate chi-square 
values for all variables.
20
 Tumor size was not included because measurement methods varied 
across patients. Patients treated prior to 2000 were more likely to have CT-based 
measurements and patients treated 2000 onwards were more likely to have MRI-based 
measurements. The minimum size for each subgroup was 10. The St. Jude dataset was used 
to construct a risk-stratification model. The CNS9702 dataset from the United Kingdom was 
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Patient Characteristics – St. Jude Cohort  
Median follow up was 11.4 years (Table 1). Median age at time of RT was 8 years. The 
following four anatomic sites were included in the analysis: optic pathway/hypothalamus, 
thalamus/midbrain, pons/medulla and cerebellum. The following histologic diagnoses were 
included in the analysis: pilocytic astrocytoma, diffuse astrocytoma and ganglioglioma. Forty 
percent of tumors involved the optic pathway or hypothalamus and 26% involved the 
thalamus or midbrain. The majority of tumors (81%) were pilocytic astrocytomas followed 
by diffuse astrocytoma (12%) and ganglioglioma (7%). Most patients underwent either a 
biopsy (53%) or STR (47%) prior to RT. Approximately a third of the patients (34%) 
received at least one course of chemotherapy prior to RT. The mean RT dose was 54 GyRBE 
and most patients were treated with photon therapy.  
Prognostic Factors For Overall Survival and Progression-Free Survival – St. Jude Cohort 
The 10-year OS and PFS for the entire St. Jude cohort was 90% (95% CI: 82.7 – 93.8) and 
66% (95% CI: 56.6% - 73.3%), r spectively. On multivariate analysis, the following 
characteristics were associated with increased risk of mortality: thalamus/midbrain location 
versus optic pathway/hypothalamic location (Hazard ratio [HR]: 6.02, 95% Confidence 
Interval [CI]: 1.35 – 26.73; p=0.018), diffuse astrocytoma versus pilocytic astrocytoma (HR: 
3.76, 95% CI: 1.18 – 11.94; p=0.025), tumor size 6 cm versus tumor size <6cm (HR: 32.6, 
95% CI: 7.72 – 137. 7; p<0.001) (Table 2).  
Inclusion of cerebral cortex tumors with a specific LGG histology (n=4) did not change the 
results of our original multivariate analysis (Supplemental Table 1). Given that extent of 
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analysis in patients who underwent biopsy alone and those who underwent STR. In the 
subgroup of patients who underwent a biopsy (n=80), thalamus/midbrain location compared 
to optic pathway/hypothalamus location remained associated with an increased risk of 
mortality (HR: 15.6, 95% CI: 2.01 – 121.74, p=0.009), and tumor size 6cm compared to 
tumor size <6cm also remained associated with an increased risk of mortality (HR: 7.38, 95% 
CI: 1.58 – 34.56, p=0.011). Similarly, in the subgroup of patients who underwent a STR 
(n=70), thalamus/midbrain location compared to optic pathway/hypothalamus location 
remained associated with an increased risk of mortality (HR: 5.77, 95% CI: 1.6 – 20.84, 
p=0.007), and tumor size 6cm compared to tumor size <6cm also remained associated with 
an increased risk of mortality (HR: 11, 95% CI: 2.92 – 41.27, p<0.001).  
On multivariate analysis, the following characteristics were associated with increased risk of 
progression: tumor size 6 cm compared to <6cm (HR: 2.84, 95% CI: 1.1 – 7.32; p=0.031) 
and delayed RT (HR: 2.53, 95% CI: 1.44 – 4.44; p=0.001) (Table 3). Delayed RT was 
defined as RT administered after at least one line of chemotherapy. Larger tumor size was 
correlated with delayed RT (p=0.002).  
Risk Groups Derived From RPA Independently Predict Survival – St. Jude Cohort 
All patients from St. Jude (n=150) were used for RPA modeling. Only variables significant 
on multivariate analysis with the exception of tumor size were included as input elements for 
the RPA. The resulting model had two splits and three terminal nodes, which were simplified 
into two risk groups (Figure 2) with statistically significant differences in OS rates (Figure 
3A). High-risk group consisted of tumors with diffuse astrocytoma histology or location 
within the thalamus/midbrain. Low-risk group consisted of tumors located outside of the 
thalamus/midbrain with either pilocytic astrocytoma or ganglioglioma histology. The 10-year 
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88.7% - 98.4% vs. 59.3% – 87.1%, p=0.003), respectively. The difference in OS between 
low-risk and high-risk groups increased over time with a 7% absolute difference at 5 years 
(5-year OS: 90.5% vs. 97%) and a 19.2% absolute difference at 10 years. Within the high-
risk group, patients who underwent delayed RT had a significantly worse OS when compared 
to those who underwent RT as first line therapy (p=0.021, Figure 3D). In the low-risk group, 
timing of RT did not influence survival (p=0.061, Figure 3E). The risk groups remained 
independently prognostic for OS after adjusting for other variables such as tumor size and 
delayed RT (high-risk vs. low-risk HR: 10.37, 95% CI: 3.5 – 30.76; p<0.001) (Supplemental 
Table 2).  
Risk Groups Retain Prognostic Significance Among Tumors with Molecular Data – St. Jude 
cohort 
Of the 49 tumors that were tested for BRAF alterations, 59% harbored a BRAF-fusion, most 
commonly KIAA1549-BRAF, and 16% harbored a BRAF V600E mutation (Table 1). Patients 
with tumors for which molecular data were available had been treated more recently and 
therefore had shorter follow-up (median: 5.8 years) (p<0.01) and were treated with more 
advanced RT techniques (p<0.001) when compared to the entire cohort. High-risk group was 
the only variable predictive of OS (HR: 15.38, 95% CI: 1.36 – 173.87; p=0.027) 
(Supplemental Table 3). The 6-year OS for low-risk (n=42) and high-risk group (n=7) was 
97.6% vs. 41.7% (95% CI: 84.3% – 99.6% vs. 1.12% - 84.2%, p=0.003), respectively (Figure 
3B). Tumors harboring BRAF V600E were not associated with worse OS or PFS when 
compared to tumors harboring BRAF fusions (Supplemental Table 4). None of the tested 
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Risk Groups Are Externally Validated Using CNS9702 Cohort   
A total of 48 patients from CNS9702 met inclusion criteria. Median follow up was 3.8 years 
from start of RT. A table of patient and tumor characteristics from CNS9702 can be found in 
Supplemental Table 5. Thirty-one percent of tumors involved the optic 
pathway/hypothalamus, 17% involved the thalamus/midbrain, 38% involved the 
pons/medulla and 15% involved in the cerebellum. The two histologies represented in the 
dataset were pilocytic astrocytoma (85%) and diffuse astrocytoma (15%). The 4-year OS for 
the low-risk group (n=35) was 100%, and that for the high-risk group (n=13) was 64.17% 
(95% CI: 30.2% – 84.3%; p<0001) (Figure 3C).  
Secondary Malignancies – St. Jude Cohort 
There were 13 subsequent malignancies, 11 of which occurred within the radiation field. 
Secondary malignancies within the RT field occurred a median of 9.05 years after the start of 
RT and included the following histologic diagnoses: anaplastic astrocytoma, gliosarcoma, 
mucoepidermoid carcinoma of the parotid gland, glioblastoma, and meningioma. The 15-year 
cumulative incidence of second malignancies was 7.03% (95% CI: 3.2% – 12.7%). One 
patient with a secondary malignancy had a known underlying genetic cancer predisposition 
syndrome (NF1). At last follow-up, three of the 11 patients with secondary malignancies 
were alive.  
Discussion 
The current management paradigm for unresectable LGG/LGGNT supports an approach of 
initially administering chemotherapy or targeted therapy and reserving RT for subsequent 
progressions with the assumption that disease outcome will not be affected by delaying RT. 
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initiation of RT. Currently, there are no validated criteria to guide use of RT. Our risk-
stratification scheme addresses this significant gap in knowledge. We demonstrate that 
children in the high-risk group with diffuse astrocytoma or thalamic/midbrain tumors have 
significantly worse OS compared to the low-risk group and delaying RT in high-risk patients 
is associated with a further decrement in OS. This decrease in OS was not apparent until after 
approximately 8 years of follow-up, highlighting the necessity of reporting long-term 
outcomes in this patient population and the need to validate these results in a larger cohort. 
RT timing did not influence survival in the low-risk patients. Delayed RT was also associated 
with worse PFS. We validated this risk-stratification in an external dataset and showed that 
risk groups retained prognostic significance independent of BRAF status. Our findings have 
important implications for unresectable LGG/LGGNTs and challenge the current treatment 
paradigm. 
It is difficult to compare our results to existing literature due to possible differences in 
reporting of histopathology and tumor location, as well as lack of long-term follow-up and 
adequate patient numbers. Interobserver agreement on histopathology can vary.
21,22
 
Therefore, central review by an experienced neuropathologist is critical and highlights a 
strength of our study. Although a large number of patients were treated on RT1, the initial 
report of RT1 did not analyze tumor histopathology or location with respect to OS or PFS.
7
 
ACNS 0221 demonstrated inferior OS in patients with non-pilocytic phenotype with a 
median follow-up of 5 years; however, diffuse astrocytoma was not analyzed as a separate 
covariate.
23
 Tumor location was also not analyzed with respect to OS or PFS. Indelicato et al. 
published outcomes after proton therapy in 174 patients with a median follow-up of 4 years.
24
 
Only age was associated with improved OS. Lower RT dose, as well as brainstem location, 
was associated with lower PFS on univariable analysis. However, since brainstem tumors 
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multivariable analysis. Furthermore, thalamic/midbrain tumors were not categorized 
separately. Other studies reporting outcomes after proton or photon therapy represent small 
and heterogeneous patient populations, limiting useful comparisons.
25–27
 However, outcomes 





 are associated with worse outcomes. Diffuse astrocytoma has also been 
associated with worse PFS in the initial report of CNS9702, which included patients who 
were observed after surgery or treated with either chemotherapy or RT.
11
 
None of the above studies has incorporated molecular data on BRAF alterations. There is a 
known association between pilocytic astrocytoma and KIAA1549-BRAF fusion, as 
approximately 70% of pilocytic astrocytomas harbor this fusion.
29
 It is unclear whether the 
fusion is associated with improved prognosis independent of tumor type, as the two are 
highly correlated. BRAF V600E mutation has been reported across multiple tumor types, 
including pilocytic astrocytoma, (pediatric-type) diffuse astrocytoma, ganglioglioma and 
pleomorphic xanthoastrocytoma.
13,30,31
 Whether this mutation is associated with independent 
prognostic significance is controversial. Lassaletta et al. reported inferior PFS in BRAF 
V600E-mutant tumors in a heterogeneous patient population treated with surgery alone, 
chemotherapy or RT.
32
 Tumor location and histopathology were not included in the analysis 
as covariates, questioning the independent prognostic significance of BRAF V600E.
33
 Our 
data shed some light on this topic, as we included both molecular and clinicopathologic data 
in our analysis. Furthermore, all patients were treated in a consistent fashion with RT, 
eliminating confounding effects from treatment heterogeneity. We did not find that BRAF 
V600E mutation was significantly associated with worse PFS or OS when compared to 
BRAF fusion in the subset of patients with molecular data (n=49).  More importantly, our 
risk stratification scheme was able to demonstrate a significant difference in OS between 
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tumor location and histopathology likely prevails over BRAF alteration for LGG/LGGNT 
treated with RT.   
Although OS was the primary outcome measure, we also analyzed PFS. We found that tumor 
size and delayed RT were associated with worse PFS. Tumor size has been correlated with 
outcomes in prior studies and was also correlated with OS in our analysis.
5,23
 The association 
between delayed RT and worse PFS might be explained through two mechanisms. First, 
tumors treated with chemotherapy prior to RT tended to be larger at the time of RT, and large 
tumor size is associated with worse PFS. However, even after accounting for tumor size, 
delayed RT remained independently associated with worse PFS. Therefore, a second 
explanation might be that pretreated tumors have shorter PFS compared to tumors that have 
not been pretreated. Pretreated tumors might be inherently more aggressive and have 
acquired additional deleterious mutations over time. The phenomenon of temporal genomic 
heterogeneity has been described in the context of pediatric gliomas.
34,35
  
The rationale for delaying or avoiding RT in young children is to reduce the risk of late 
effects, such as cerebral vasculopathy, neurocognitive impairment, endocrine deficiencies and 
secondary malignancies. In the context of pediatric brain tumors, the reported cumulative 
incidence of a second malignancy is approximately 6% to 8% at 20 to 30 years, which is 
comparable to our result of 7% at 15 years.
36,37
 In the setting of LGG, distinction between a 
secondary malignancy and transformation can be challenging – approximately 3% of 
pediatric LGG may transform to a secondary high-grade glioma.
38
 Some patients with LGG 
may also harbor cancer predisposition syndromes, such as NF1, and be more susceptible to 
develop a subsequent malignancy. Along with young age, region and volume of brain being 
irradiated are significant risk factors for vasculopathy, neurocognitive effects and endocrine 
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 irradiation of the hippocampus can impair memory and learning,
40
 and 
irradiation of the pituitary-hypothalamic axis can result in endocrine deficiencies.
41
  
There are several limitations to our analysis. BRAF alterations were only determined in a 
subset of St. Jude patients (n=49). Similarly, absence of H3 K27M mutation was confirmed 
in a subset of patients with thalamic/midbrain tumors for whom data were available (n=26). 
Additionally, the validation cohort from CNS9702 did not contain any molecular data. 
Although we did not find any statistically significant difference in outcome by BRAF 
alteration, our subset with molecular data was limited. Therefore, we cannot exclude the 
possibility that BRAF alterations might be associated with a difference in outcome. With 
additional molecular data, as well as MRI-based tumor measurements, further refinement of 
the risk stratification scheme might be possible. There is some difficulty in interpreting tumor 
size over a two-decade timespan with evolving imaging technologies from CT to high-
resolution MRI.  Secondly, although RPA is a clinically useful tool to divide patients into 
prognostic groups, the results can be highly dependent on patient population and input 
variables. Therefore, it is reassuring that we can reproduce statistically significant differences 
in the low-risk and high-risk groups using an independent dataset. Finally, application of our 
risk stratification scheme should be limited to unresectable LGG/LGGNT treated with RT. 
The validity of this risk scheme in other clinical contexts is unknown.  
We have identified a high-risk group of patients with diffuse astrocytoma or 
thalamic/midbrain tumors associated with inferior survival and validate these results using an 
external dataset. Risk grouping retained prognostic significance independent of BRAF 
alteration. In this high-risk group, delayed RT was associated with a reduction in OS, 
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Figure 1. CONSORT Diagram 
Figure 2. Results of recursive partitioning analysis of St. Jude cohort  
Figure 3. Overall survival stratified by risk group for: (A) the entire St. Jude cohort, (B) the 
patients in the St. Jude cohort with molecular data stratified by risk group, and (C) the 
external validation dataset (the CNS9702 cohort). Overall survival stratified by timing of RT 
in: (D) high-risk group, and (E) low-risk group. Delayed RT is defined as RT after at least 
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Table 1. Patient and Tumor Characteristics of the St. Jude Cohort 







Median follow-up years (range) 11.4 (0.24–29.4) 5.83 (0.24–20.6) <0.01 
Median age in years (range) 8 (1.2–20) 7.9 (2.2–18.4) 0.616 
Sex (%) 
  Female 









  White 
  Black 











  Yes 








Tumor location (%) 
  OPG/hypothalamus 
  Thalamus/midbrain 
  Pons/medulla 













 Pilocytic astrocytoma 











BRAF alteration (N = 49) (%) 
  BRAF V600E 
  BRAF fusion 










Tumor size before RT (%) 
  <6 cm 








Surgical extent (%) 
  Biopsy 








Number of surgeries before RT 
(%) 
  1  
  2 










Chemotherapy before RT (%) 
  Yes 








Radiation modality (%) 
  3D CRT  
  IMRT 








7 (14)  
<0.001 
Mean radiation dose in GyRBE 
(range)  
54 (48–55.8) 54 (50.4–54) 0.329 
α
P value for frequency distributions based on Fisher exact test for categorical variables and Wilcoxon 
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NF1 = neurofibromatosis-1; OPG = optic pathway glioma; RT = radiation therapy; GTR = gross total 
resection; STR = subtotal resection; CRT = conformal radiation therapy; IMRT = intensity-modulated 
radiation therapy 
 
Table 2. Univariate and multivariate analysis of overall survival in the St. Jude cohort 
Univariate Analysis   Multivariate 
Analysis 
Variable  HR (95% CI) P HR (95% CI) P 
Sex  
  Male 











  Caucasian 
  Black  













Age at RT  0.99 (0.89–1.10) 0.853   
Location 
  OPG/hypothalamus 
  Thalamus/midbrain 
  Pons/medulla 






















  Pilocytic astrocytoma 
  Diffuse astrocytoma 
  Ganglioglioma 
 
1 














Tumor size before RT  
  <6 cm 













BRAF alteration (N = 49) 
  BRAF fusion 
  BRAF WT 










Chemotherapy before RT 
  No 
  Yes 
 
1 










RT dose (GyRBE) 1 (0.99–1)  0.804   
NF1  
  No 









  Biopsy 
  STR 










Number of surgeries before RT 
  1  
  2 










NF1 = neurofibromatosis-1; OPG = optic pathway glioma; RT = radiation therapy; GTR = gross total 
resection; STR = subtotal resection; CRT = conformal radiation therapy; IMRT = intensity-modulated 
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Table 3. Variables significant on univariate analysis of progression-free survival in the St. Jude 
cohort 




  HR (95% CI) P HR (95% CI) P 
Age at RT  0.91 (0.85–0.98) 0.014 - NS 
Tumor size before RT  
  6 cm 















  No 
  Yes 
 
1 











Only variables that were significant on univariate analysis are listed.  
α
Delayed RT is defined as RT after at least one line of chemotherapy.  
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